Where does Signal Pharmaceuticals, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Signal Pharmaceuticals, LLC ranks #4,534 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Signal Pharmaceuticals, LLC hold?

Signal Pharmaceuticals, LLC holds 78 US utility patents granted between 2015 and 2024, spanning 8 technology areas.

What is Signal Pharmaceuticals, LLC's Innovation Score?

Signal Pharmaceuticals, LLC has an Innovation Score of 38.2 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Signal Pharmaceuticals, LLC's patent grant rate increasing or decreasing?

Signal Pharmaceuticals, LLC's recent grant velocity is -76% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Signal Pharmaceuticals, LLC's patents?

Signal Pharmaceuticals, LLC's patents average 18.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Signal Pharmaceuticals, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Signal Pharmaceuticals, LLC

Q: What technology areas does Signal Pharmaceuticals, LLC focus on?

Signal Pharmaceuticals, LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 70 patents. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 78 granted patents across 8 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Signal ranks #4,534 of 49,997 tracked US assignees by granted-patent volume, with 78 patents across 8 technology areas.

#4,534
of 49,997 US assignees by volume: Top 41%
by Innovation Score (38.2/100): 18.1
avg claims per patent: -76%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4534 · US Corporation #4,534 · 78 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 78 grants
TOP-DECILE #4,534/49,997
PHOTO-FINISH Phoseon Technology
CPC-NARROW A61P · 8 areas
INNOV-THIN 38.2/100
CLAIMS-RICH 18.1 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -76% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Phoseon Technology, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Byton · near

38
Centre Firearms · near

38
Hikma Pharmaceutical… · near

38
Signal Pharmaceuticals · this assignee

38
Pixia · near

38
3D Lighting… · lowest

7

What this shows Signal's Innovation Score is 38.2/100 (top 41% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Signal's grants concentrate

Signal Pharmaceuticals, LLC is a focused PatentsView assignee: 8 CPC subclasses with 89.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (19 grants) versus a trough of 1 in 2023. By volume, Signal sits between Phoseon Technology, Inc. and Universitat Stuttgart.

Signal's three-year grant acceleration

Signal Pharmaceuticals, LLC shows 6 grants in 2022–2024 against only 18 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Phoseon Technology

78
R R Donnelley & S…

78
Shenzhen Verdewel…

78
Sifive

78
Teledyne Instrume…

78
Tendyne Holdings

78
Truecar

78
Universitat Stutt…

78
Signal Pharmaceut… ◀

78

What this shows Signal holds 78 patents at rank #4,534, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Signal

By rank, the assignees closest to #4,534 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Signal's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Signal, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Byton Limited 38 Centre Firearms Co., Inc. 38 Hikma Pharmaceuticals USA Inc. 38 Pixia Corp. 38

Similar claim depth

Nearest assignees by average claims per patent (18.1 here).

M31 Technology Corporation 18.1 avg Newport Fab, LLC 18.1 avg Aleddra Inc. 18.1 avg Sony Electronics Inc. 18.1 avg

Signal's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 41% higher than 59% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Signal Pharmaceuticals, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	9.0%
2016	15	19.2%
2017	19	24.4%
2018	13	16.7%
2019	9	11.5%
2020	5	6.4%
2021	4	5.1%
2022	4	5.1%
2023	1	1.3%
2024	1	1.3%

Which technologies does Signal Pharmaceuticals, LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 70

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 64

C07D - Heterocyclic Compounds 63

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 12

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C07C - Acyclic OR Carbocyclic Compounds 1

C07K - Peptides 1

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#4,534

of 49,997 tracked assignees

Innovation Score

38.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Signal Pharmaceuticals, LLC's patent record in context - here's where to go next.

Signal Pharmaceuticals, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 89.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,534 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Signal Pharmaceuticals, LLC against Phoseon Technology, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.